Biodesix Inc. (BDSX) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil prices, Treasury yields remain elevated
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Oppenheimer sees AI software winners as focus shifts to ROI
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
Biodesix Announces First Quarter 2022 Results and Highlights
May 11, 2022 6:00 AM EDTFirst quarter 2022 core Lung Diagnostic revenue of $4.6 million increased 17% over the comparable period in 2021;
Continued to strengthen financial position through an additional $27.4 million in debt and equity funding during second quarter 2022;
Conference Call and Webcast Today at 8:00 a.m. ET
BOULDER, Colo.--(BUSINESS WIRE)--... More
